Clinical trials: Hyperphosphatemia Patients on Peritoneal Dialysis
Peritoneal Dialysis Complication, Hyperphosphatemia
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.
- Conditions
- Peritoneal Dialysis Complication, Hyperphosphatemia, Hypoalbuminemia
- Trial name
- NCT04046263
- Testing
- Sucroferric Oxyhydroxide Chewable Tablet
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Hyperphosphatemia, Kidney Failure
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
- Trial name
- NCT01191255
- Where
- 56 sites in United States, Israel and 1 more
- Volunteers
- 441 people
- Sponsor
- Keryx Biopharmaceuticals